- Home
- LNTH vs TMDX Comparison
LNTH vs TMDX Comparison
Compare LNTH & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LNTH
- TMDX
- Stock Information
- Founded
- LNTH 1956
- TMDX 1998
- Country
- LNTH United States
- TMDX United States
- Employees
- LNTH N/A
- TMDX N/A
- Industry
- LNTH Biotechnology: In Vitro & In Vivo Diagnostic Substances
- TMDX Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- LNTH Health Care
- TMDX Health Care
- Exchange
- LNTH Nasdaq
- TMDX Nasdaq
- Market Cap
- LNTH 3.8B
- TMDX 3.9B
- IPO Year
- LNTH 2015
- TMDX 2019
- Fundamental
- Price
- LNTH $53.42
- TMDX $117.33
- Analyst Decision
- LNTH Buy
- TMDX Buy
- Analyst Count
- LNTH 6
- TMDX 11
- Target Price
- LNTH $74.17
- TMDX $130.73
- AVG Volume (30 Days)
- LNTH 1.3M
- TMDX 1.0M
- Earning Date
- LNTH 11-06-2025
- TMDX 10-29-2025
- Dividend Yield
- LNTH N/A
- TMDX N/A
- EPS Growth
- LNTH N/A
- TMDX 170.70
- EPS
- LNTH 2.39
- TMDX 2.54
- Revenue
- LNTH $1,525,933,000.00
- TMDX $566,354,000.00
- Revenue This Year
- LNTH N/A
- TMDX $38.84
- Revenue Next Year
- LNTH $1.98
- TMDX $20.46
- P/E Ratio
- LNTH $22.36
- TMDX $46.16
- Revenue Growth
- LNTH 1.95
- TMDX 41.20
- 52 Week Low
- LNTH $47.25
- TMDX $55.00
- 52 Week High
- LNTH $111.29
- TMDX $145.50
- Technical
- Relative Strength Index (RSI)
- LNTH 46.61
- TMDX 45.02
- Support Level
- LNTH $51.47
- TMDX $111.04
- Resistance Level
- LNTH $55.55
- TMDX $125.57
- Average True Range (ATR)
- LNTH 2.67
- TMDX 7.52
- MACD
- LNTH -0.30
- TMDX -1.59
- Stochastic Oscillator
- LNTH 28.53
- TMDX 19.88
About LNTH Lantheus Holdings Inc.
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.
About TMDX TransMedics Group Inc.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.